Why Juno Therapeutics Shares Vaulted 46% Higher in August
After Gilead Sciences (NASDAQ: GILD) scooped up competitor Kite Pharma (NASDAQ: KITE) for $11.9 billion and Novartis (NYSE: NVS) secured an approval from the Food and Drug Administration for Kymriah, shares of Juno Therapeutics (NASDAQ: JUNO) skyrocketed 46% in August, according to S&P Global Market Intelligence.
Juno Therapeutics hasn't been in the lead in the race to develop cellular therapies for cancer treatment for a while, but that didn't stop investors from flocking to its shares following key advances at its top CAR-T competitors.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Gilead Sciences Inc Stock
€70.94
0.440%
We see a rather positive sentiment for Gilead Sciences Inc with 11 Buy predictions and 1 Sell predictions.
With a target price of 85 € there is a slightly positive potential of 19.82% for Gilead Sciences Inc compared to the current price of 70.94 €.
